Immix Biopharma, Inc.
About Immix Biopharma, Inc.
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc. is headquartered in Los Angeles, CA.
What problem does Immix Biopharma, Inc. solve?
There are no FDA-approved drugs for relapsed/refractory AL Amyloidosis, and current treatments produce only a 0-10% complete response rate.
What's Immix Biopharma, Inc.'s solution?
Immix developed NXC-201, a one-time CAR-T therapy that re-engineers a patient's own immune system to eliminate the diseased cells causing AL amyloidosis at the root cause.
What makes Immix Biopharma, Inc. different?
They claim three proprietary modifications (optimized CD3ζγ signaling, enhanced CD8 hinge, COBRA Binder technology) that deliver precise 'digital' signaling, plus zero neurotoxicity and the shortest cytokine release syndrome duration of any BCMA CAR-T in clinical results.
What makes Immix Biopharma, Inc. notable?
Founded and led by Ilya Rachman, a physician-scientist and former UCLA clinical faculty member; the company trades publicly on Nasdaq under ticker IMMX.
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.